Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Miltefosine is an antileishmanial agent used to treat leishmaniasis, a group of disease caused by parasites of the Leishmania type. Miltefosine is a broad spectrum antimicrobial, anti-leishmanial, phospholipid drug that was originally developed in the 1980s as an anti-cancer agent.
- Mechanism
- Curator reviewed
Miltefosine has demonstrated activity against Leishmania parasites and neoplastic cells primarily due to its effects on apoptosis and disturbance of lipid-dependent cell signalling pathways. Several potential antileishmanial mechanisms of action have been proposed, however no mechanism has been identified definitely. Within the mitochondria, miltefosine inhibits cytochrome-c oxidase leading to mitochondrial dysfunction and apoptosis-like cell death. Antineoplastic mechanisms of action are related to antileishmanial targets and include inhibition of phosphatidylcholine biosynthesis and inhibition of Akt (also known as protein kinase B), which is a crucial protein within the PI3K/Akt/mTOR intracellular signalling pathway involved in regulating the cell cycle. Animal studies also suggest it may be effective against Trypanosome cruzi (the organism responsible for Chagas' disease), metronidazole-resistant strains of Trichonomas vaginalis, and it may have broad-spectrum anti-fungal activity.
- Primary indication
- For the treatment of mucosal (caused by Leishmania braziliensis), cutaneous (caused by L. braziliensis, L. guyanensis, and L. panamensis), and visceral leishmaniasis (caused by L. donovani).Curator reviewed · 4 structured indications
- Formula / weight
- C21H46NO4P · 407.576 g/mol (avg)
- First approval
- United States, 2014
- Also known as
- HDPC · Hexadecylphosphocholine · Hexadecylphosphorylcholine · Monohexadecylphosphocholine · Monohexadecylphosphorylcholine
- Code names
- D-18506
Resolves to
PQLXHQMOHUQAKB-UHFFFAOYSA-NSMILESCCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)CWhat you can answer from here — as of September 28, 2026
Which drugs share a target with Miltefosine, and which of those have an active Phase 3 trial?